ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
This includes 14.3 million views on YouTube and 9.8 million views on Meta platforms to amplify preventive heart health message
Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals
The study was conducted by PwC India in line with ISO 14040 and ISO 14044 protocols
The launch coincides with IBS Awareness Month in April
Narasimhan’s appointment underscores the growing importance of AI in transforming drug discovery
The investment will support the company’s plans to expand its network of specialised surgical hospitals across India.
Subscribe To Our Newsletter & Stay Updated